

A. Recurrent BCC of any size, or unexpected positive margin on recent excision (healthy or immunocompromised patients, or patients with genetic syndromes)

		Appropriate use score (1-9)		
Indication	Pathology	Area H	Area M	Area L
1	Aggressive	A (9)	A (9)	A (7)
2	Nodular	A (9)	A (8)	A (7)
3	Superficial	A (7)	A (7)	I (3)

B. Primary aggressive BCC (healthy or immunocompromised patients)

		Appropriate use score (1-9)		
Indication	Size, cm	Area H	Area M	Area L
4	≤0.5	A (8)	A (8)	U (6)
5	0.6-1	A (9)	A (8)	A (7)
6	1.1-2	A (9)	A (9)	A (8)
7	>2	A (9)	A (9)	A (8)

C. Primary nodular BCC (healthy patients)

		Appropriate use score (1-9)		
Indication	Size, cm	Area H	Area M	Area L
8	≤0.5	A (7)	A (7)	I (3)
9	0.6-1	A (8)	A (8)	I (3)
10	1.1-2	A (9)	A (8)	U (6)
11	>2	A (9)	A (9)	A (7)

D. Primary nodular BCC (immunocompromised patients)

		Appropriate use score (1-9)		
Indication	Size, cm	Area H	Area M	Area L
12	≤0.5	A (8)	A (7)	I (3)
13	0.6-1	A (9)	A (8)	U (5)
14	1.1-2	A (9)	A (9)	A (7)
15	>2	A (9)	A (9)	A (7)

E. Primary superficial BCC (healthy patients)

		Appropriate use score (1-9)		
Indication	Size, cm	Area H	Area M	Area L
16	≤0.5	A (7)	U (4)	I (1)
17	0.6-1	A (7)	A (7)	I (3)
18	1.1-2	A (7)	A (7)	I (3)
19	>2	A (8)	A (8)	I (3)

F. Primary superficial BCC (immunocompromised patients)

		Appropriate use score (1-9)		
Indication	Size, cm	Area H	Area M	Area L
20	≤0.5	A (7)	A (7)	I (2)
21	0.6-1	A (8)	A (7)	I (3)
22	1.1-2	A (8)	A (7)	U (5)
23	>2	A (8)	A (8)	U (5)

A. Recurrent SCC of any size or unexpected positive margin on recent excision (healthy or immunocompromised patients, or patients with genetic syndromes)				
		Appropriate use score (1-9)		
Indication	Pathology	Area H	Area M	Area L
24	Aggressive	A (9)	A (9)	A (8)
25	Verrucous	A (9)		
26	KA-type SCC (not central facial)	A (8)	A (8)	A (7)
27	In situ/Bowen	A (7)	A (7)	U (6)
28	AK with focal SCC in situ; Bowenoid AK; SCC in situ, AK type	I (2)	I (2)	I (2)
29	Without aggressive histologic features, <2-mm depth without other defining features, Clark level ≤III	A (8)	A (8)	A (7)
B. Primary aggressive SCC (healthy patients)				
		Appropriate use score (1-9)		
Indication	Size, cm	Area H	Area M	Area L
30	≤0.5	A (8)	A (8)	A (7)
31	0.6-1	A (9)	A (8)	A (7)
32	1.1-2	A (9)	A (9)	A (7)
33	>2	A (9)	A (9)	A (8)
C. Primary aggressive SCC (immunocompromised patients)				
		Appropriate use score (1-9)		
Indication	Size, cm	Area H	Area M	Area L
34	≤0.5	A (9)	A (8)	A (7)
35	0.6-1	A (9)	A (8)	A (7)
36	1.1-2	A (9)	A (9)	A (8)
37	>2	A (9)	A (9)	A (9)
D. Primary SCC; without aggressive histologic features, <2-mm depth without other defining features, Clark level ≤III (healthy patients)				
		Appropriate use score (1-9)		
Indication	Size, cm	Area H	Area M	Area L
38	≤0.5	A (8)	A (7)	I (3)
39	0.6-1	A (8)	A (7)	I (3)
40	1.1-2	A (8)	A (8)	U (6)
41	>2	A (9)	A (9)	A (7)
E. Primary SCC; without aggressive histologic features, <2-mm depth without other defining features, Clark level ≤III (immunocompromised patients)				
		Appropriate use score (1-9)		
Indication	Size, cm	Area H	Area M	Area L
42	≤0.5	A (8)	A (8)	U (5)
43	0.6-1	A (9)	A (8)	U (6)
44	1.1-2	A (9)	A (9)	A (7)
45	>2	A (9)	A (9)	A (8)
F. Primary verrucous SCC (healthy or immunocompromised patients)				
		Appropriate use score (1-9)		
Indication	Size, cm	Area H	Area M	Area L
46	≤0.5	A (8)		
47	0.6-1	A (8)		
48	1.1-2	A (9)		
49	>2	A (9)		

G. Primary SCC KA-type; not central facial (healthy patients)			
		Appropriate use score (1-9)	
Indication	Size, cm	Area H	Area L
50	≤0.5	A (7)	I (2)
51	0.6-1	A (8)	I (3)
52	1.1-2	A (9)	A (7)
53	>2	A (9)	A (7)
H. Primary SCC KA-type; not central facial (immunocompromised patients)			
		Appropriate use score (1-9)	
Indication	Size, cm	Area H	Area L
54	≤0.5	A (8)	U (6)
55	0.6-1	A (8)	A (7)
56	1.1-2	A (9)	A (7)
57	>2	A (9)	A (8)
I. Primary in situ SCC/Bowen disease (healthy patients)			
		Appropriate use score (1-9)	
Indication	Size, cm	Area H	Area L
58	≤0.5	A (7)	I (2)
59	0.6-1	A (7)	I (2)
60	1.1-2	A (8)	U (6)
61	>2	A (9)	A (7)
J. Primary in situ SCC/Bowen disease (immunocompromised patients)			
		Appropriate use score (1-9)	
Indication	Size, cm	Area H	Area L
62	≤0.5	A (8)	I (3)
63	0.6-1	A (8)	U (4)
64	1.1-2	A (8)	A (7)
65	>2	A (9)	A (7)
K. Primary AK with focal SCC in situ; Bowenoid AK; SCC in situ, AK type (healthy patients)			
		Appropriate use score (1-9)	
Indication	Size, cm	Area H	Area L
66	≤0.5	I (3)	I (1)
67	0.6-1	I (3)	I (1)
68	1.1-2	I (3)	I (1)
69	>2	I (3)	I (2)
L. Primary AK with focal SCC in situ; Bowenoid AK; SCC in situ, AK type (immunocompromised patients)			
		Appropriate use score (1-9)	
Indication	Size, cm	Area H	Area L
70	≤0.5	I (2)	I (1)
71	0.6-1	I (2)	I (2)
72	1.1-2	I (2)	I (2)
73	>2	I (2)	I (2)

A. Primary lentigo maligna (healthy or immunocompromised patients)

	Appropriate use score (1-9)		
Indication	Area H	Area M	Area L
75	A (8)	A (7)	U (4)

B. Locally recurrent lentigo maligna (healthy or immunocompromised patients)

	Appropriate use score (1-9)		
Indication	Area H	Area M	Area L
76	A (8)	A (8)	A (7)

C. Primary melanoma in situ; non-lentigo maligna (healthy or immunocompromised patients)

	Appropriate use score (1-9)		
Indication	Area H	Area M	Area L
77	A (7)	A (7)	U (5)

D. Locally recurrent melanoma in situ; non-lentigo maligna (healthy or immunocompromised patients)

	Appropriate use score (1-9)		
Indication	Area H	Area M	Area L
78	A (8)	A (7)	A (7)

Primary or recurrent (healthy or immunocompromised patients)		Appropriate use score (1-9)		
Indication	Cancer type	Area H	Area M	Area L
79	Adenocystic carcinoma	A (9)	A (8)	A (7)
80	Adnexal carcinoma	A (9)	A (8)	A (7)
81	Apocrine/eccrine carcinoma	A (8)	A (8)	A (8)
82	Angiosarcoma	U (5)	U (5)	U (5)
83	AFX	A (9)	A (8)	A (7)
84	Bowenoid papulosis	I (3)		
85	DFSP	A (9)	A (9)	A (9)
86	Desmoplastic trichoepithelioma	U (6)	U (5)	I (3)
87	EMPD	A (8)	A (8)	A (7)
88	Leiomyosarcoma	A (8)	A (8)	A (7)
89	MFH/undifferentiated pleomorphic sarcoma	A (8)	A (8)	A (7)
90	MCC	A (8)	A (7)	U (5)
91	MAC (sclerosing sweat duct carcinoma)	A (9)	A (9)	A (8)
92	Mucinous carcinoma	A (8)	A (8)	A (7)
93	Sebaceous carcinoma	A (9)	A (8)	A (7)
94	Rare biopsy-proven malignancies not otherwise specified	U (5)	U (5)	U (5)